2,6-dihydroxy-3-cyanopyridine has been researched along with fluorouracil in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, S; Fukushima, M; Imaoka, T; Motoyama, M; Ohshimo, H; Shimamoto, Y; Shirasaka, T | 1 |
| Fujii, S; Fukushima, M; Imaoka, T; Ohshimo, H; Shimamoto, Y; Shirasaka, T | 1 |
| Fujii, S; Fukushima, M; Shimamoto, Y; Shirasaka, T | 1 |
| Fujii, S | 1 |
| Hayashi, K; Imaoka, T; Kawaguchi, T; Kubo, M; Matsui, Y; Miyauchi, S; Utsunomiya, T | 1 |
| Miyauchi, S; Okayasu, T; Sugiyama, K | 1 |
| Imaoka, T; Kawaguchi, T; Kishi, K; Kiyono, K; Kubo, M; Tatsumi, K; Yamauchi, T; Yanagihara, Y | 1 |
| Harada, M; Kimura, A; Koga, K; Miura, I; Nishitani, H | 1 |
8 other study(ies) available for 2,6-dihydroxy-3-cyanopyridine and fluorouracil
| Article | Year |
|---|---|
Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Fluorouracil; Infusions, Intravenous; Male; Neoplasm Transplantation; Pyridines; Rats; Sarcoma, Yoshida | 1989 |
Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Fluorouracil; Mice; Mice, Inbred ICR; Pyridines; Rats; Sarcoma 180; Sarcoma, Yoshida | 1989 |
Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Drug Synergism; Fluorouracil; Infusions, Intravenous; Kinetics; Leukocyte Count; Pyridines; Rats; Sarcoma, Yoshida; Tegafur; Uracil | 1989 |
[BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Floxuridine; Fluorouracil; Liver; Mice; Pyridines; Pyrimidines; Rats; Sarcoma 180; Sarcoma, Experimental; Sarcoma, Yoshida; Tegafur; Uracil | 1987 |
Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Combinations; Drug Interactions; Fluorouracil; Lung; Lung Neoplasms; Male; Neoplasm Transplantation; Pyridines; Rats; Sarcoma, Yoshida; Tegafur; Transplantation, Heterologous; Uracil | 1994 |
Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Pyridines | 1994 |
3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
Topics: Alanine; Animals; Antineoplastic Agents; Dihydrouracil Dehydrogenase (NAD+); Drug Synergism; Fluorouracil; Male; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Phosphorylation; Pyridines; Rats; Rats, Inbred Strains; Sarcoma, Yoshida; Tumor Cells, Cultured; Uracil | 1993 |
Comparative studies on the metabolism of new fluorinated pyrimidine drugs in the liver by in vivo 19F magnetic resonance spectroscopic observation.
Topics: Alanine; Animals; Dihydrouracil Dehydrogenase (NAD+); Drug Interactions; Fluorouracil; Liver; Magnetic Resonance Spectroscopy; Male; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pyridines; Rats; Rats, Wistar; Tegafur; Uracil | 1993 |